A Phase 2B expanded safety and immunogenicity trial is being carried out in the Kambia District of Sierra Leone by the EBOVAC1 consortium, in partnership with the College of Medicine and Allied Health Sciences (Sierra Leone), under the name EBOVAC-Salone. This large scale safety and immunogenicity study is helping us to learn as much as possible about how the vaccines work in people who live in an area affected by Ebola.

The first participants in the EBOVAC-Salone study were vaccinated in early October 2015. Read more about the study start.

EBOVAC-Salone staff on the day of the study’s first vaccination (Credit: John Connelly)